Jounce Therapeutics Inc. (NASDAQ: JNCE) is -13.75% lower on its value in year-to-date trading and has touched a low of $2.79 and a high of $10.00 in the current 52-week trading range. The JNCE stock was last observed hovering at around $4.84 in the last trading session, with the day’s gains setting it 2.69% off its average median price target of $11.00 for the next 12 months. It is also 49.8% off the consensus price target high of $15.00 offered by 6 analysts, but current levels are -36.91% lower than the price target low of $5.50 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $7.53, the stock is 56.11% and 38.78% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 43.05 million and changing 55.58% at the moment leaves the stock 31.27% off its SMA200. JNCE registered 117.00% gain for a year compared to 6-month loss of 43.16%. The firm has a 50-day simple moving average (SMA 50) of $4.92 and a 200-day simple moving average (SMA200) of $5.14.
The stock witnessed a 57.20% gain in the last 1 month and extending the period to 3 months gives it a 34.22%, and is 44.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.94% over the week and 8.09% over the month.
Jounce Therapeutics Inc. (JNCE) has around 130 employees, a market worth around $245.18M and $119.40M in sales. Current P/E ratio is 12.22. Profit margin for the company is 18.20%. Distance from 52-week low is 169.89% and -24.70% from its 52-week high. The company has generated returns on investments over the last 12 months (30.20%).
Jounce Therapeutics Inc. (JNCE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Jounce Therapeutics Inc. (JNCE) is a “Hold”. 6 analysts offering their recommendations for the stock have an average rating of 2.30, where 2 rate it as a Hold and 1 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Jounce Therapeutics Inc. is expected to release its quarterly report on 11/17/2020 and quarterly earnings per share for the current quarter are estimated at -$0.67 with sales reaching $2M over the same period.The EPS is expected to grow by 297.10% this year, but quarterly earnings will post -97.70% year-over-year.
Jounce Therapeutics Inc. (JNCE) Top Institutional Holders
146 institutions hold shares in Jounce Therapeutics Inc. (JNCE), with 4.39M shares held by insiders accounting for 12.88% while institutional investors hold 85.68% of the company’s shares. The shares outstanding are 34.05M, and float is at 30.38M with Short Float at 7.15%. Institutions hold 74.64% of the Float.
The top institutional shareholder in the company is TRV GP II, LLC with over 10.23 million shares valued at $70.59 million. The investor’s holdings represent 30.03% of the JNCE Shares outstanding. As of Jun 29, 2020, the second largest holder is TRV GP III, LLC with 3.05 million shares valued at $21.04 million to account for 8.95% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.27 million shares representing 3.73% and valued at over $8.77 million, while Dimensional Fund Advisors LP holds 3.36% of the shares totaling 1.15 million with a market value of $7.9 million.
Jounce Therapeutics Inc. (JNCE) Insider Activity
A total of 9 insider transactions have happened at Jounce Therapeutics Inc. (JNCE) in the last six months, with sales accounting for 9 and purchases happening 0 times. The most recent transaction is an insider sale by Drapkin Kimberlee C, the company’s CFO and Treasurer. SEC filings show that Drapkin Kimberlee C sold 744 shares of the company’s common stock on Aug 18 at a price of $4.71 per share for a total of $3504.0. Following the sale, the insider now owns 68908.0 shares.
Jounce Therapeutics Inc. disclosed in a document filed with the SEC on Aug 18 that Cole Hugh M (Chief Business Officer) sold a total of 744 shares of the company’s common stock. The trade occurred on Aug 18 and was made at $4.71 per share for $3504.0. Following the transaction, the insider now directly holds 61408.0 shares of the JNCE stock.
Still, SEC filings show that on Aug 17, Cole Hugh M (Chief Business Officer) disposed off 454 shares at an average price of $4.86 for $2206.0. The insider now directly holds 62,152 shares of Jounce Therapeutics Inc. (JNCE).
Jounce Therapeutics Inc. (JNCE): Who are the competitors?
The company’s main competitors (and peers) include Momenta Pharmaceuticals Inc. (MNTA) that is trading 328.16% up over the past 12 months. Short interest in the company’s stock has fallen -1.84% from the last report on Jul 14, 2020 to stand at a total of 2.21 million short shares sold with a short interest ratio of 12.57.